Objectives: To determine the levels of resistance to ciprofloxacin among non-typhoidal salmonellae in Scotland.
Introduction
Salmonellosis is usually a self-limiting diarrhoeal disease requiring little or no medical intervention. However, in cases of invasive disease or infections with added complications, such as at the extremities of age or in the presence of underlying disease, antimicrobial treatment may be required. In these cases, quinolones and fluoroquinolones have proven very effective, with ciprofloxacin (a second-generation quinolone) being the therapeutic agent of choice for the treatment of a number of illnesses including typhoid fever and invasive Salmonella Virchow infections.
1,2 Unfortunately, treatment failures have been reported, due to increasing resistance to these antimicrobial compounds. [3] [4] [5] [6] Reports from the Indian subcontinent, [7] [8] [9] Southeast Asia 10, 11 and Africa 12 describe treatment failures in areas where typhoid fever is endemic. Many European countries have also noted increased resistance to quinolones. In 1996 in England and Wales, 12% of S. Typhimurium isolates were resistant to ciprofloxacin at 0.125 mg/L, a 12-fold increase since 1994. 13 Recent figures from Denmark show that the incidence of nalidixic acid-resistant zoonotic salmonella infections rose from 0.8% in 1995 to 8.5% in 2000. 14 The USA is also monitoring the emergence of quinoloneresistant Salmonella. In 1996, 0.4% of non-Typhi Salmonella isolates had decreased susceptibility (MIC ‡ 0.25 mg/L) to ciprofloxacin. In 2001, that figure had risen to 1% with 0.2% of these classed as resistant to ciprofloxacin. 15 Quinolone and fluoroquinolone antimicrobials inhibit tertiary supercoiling of bacterial DNA, primarily by inhibiting the action of DNA gyrase, a Type II topoisomerase, which consists of two GyrA and two GyrB subunits encoded by gyrA and gyrB, respectively.
A single point mutation in gyrA between amino acids 67 and 106 (known as the quinolone resistance-determining region or QRDR) can give rise to nalidixic acid (a first-generation quinolone) resistance among isolates of Salmonella. This resistance is usually accompanied by a reduction in the susceptibility of these isolates to ciprofloxacin. 16, 17 All Salmonella isolates of human, veterinary and environmental origin received by the Scottish Salmonella Reference Laboratory (SSRL) are tested for susceptibility against a panel of 14 antibiotics, including nalidixic acid (40 mg/L) and ciprofloxacin (0.125 mg/L and 0.5 mg/L) using a validated in-house breakpoint method. Data from these tests indicated an increase in the This study was undertaken to fully characterize the levels of resistance to ciprofloxacin observed in non-Typhoidal Salmonella serotypes in Scotland over the 10 year period 1993-2003. Accurate MIC data are essential to allow the assessment of any trend towards reduced susceptibility to ciprofloxacin in nalidixic acid-resistant clinical isolates.
Materials and methods

Bacterial isolates
All Salmonella isolates used in this study were taken from the SSRL culture collection of strains isolated in Scotland.
Selection was based on the following criteria: (i) human origin; (ii) nalidixic acid-resistant by breakpoint method; (iii) received by SSRL during 1993, 1998 and 2003. Quality control strains and duplicate samples were excluded and only a single isolate from epidemiologically related outbreaks was included.
In total, 493 isolates of Salmonella were included in the study (Tables 1 and 2) .
Escherichia coli ATCC 25922 and Salmonella Enteritidis PT6a SSRL 20002621 were included as MIC controls.
Isolates were stored on Dorset Egg slopes at room temperature.
Media
Isolates were inoculated onto cysteine lactose electrolyte deficient (CLED) agar (DM110; Mast Diagnostics, Merseyside, England) plates and incubated overnight at 37 C. For susceptibility tests, MacConkey agar (CM507; Oxoid, Hampshire, England), diagnostic sensitivity agar (CM261; Oxoid) and tryptone water (tryptone, L42 oxoid, 1% w/v; sodium chloride, 301325Q, VWR International Ltd, Leicester, England; distilled water, pH 7.4) were used. Nalidixic acid was purchased from Sigma-Aldrich (N-4382), Dorset, England. For Etests, Mueller-Hinton agar plates were purchased from E & O Laboratories, Bonnybridge, Scotland.
Susceptibility testing by breakpoint
A single colony from an overnight MacConkey agar plate was resuspended in 3 mL of tryptone water and incubated at 37 C for 4 h; 100 mL was then inoculated into 3 mL of sterile water, 0.5 mL of which was transferred into a well in a perspex block. Diagnostic sensitivity agar plates containing known concentrations of antibiotic (for nalidixic acid, 40 mg/L) were inoculated with the bacterial dilutions from the perspex block using a Lidwell multipoint inoculator. The plates were allowed to dry and were incubated overnight at 37 C. (35) 12 (20) n, Total number of isolates received by SSRL.
Ciprofloxacin resistance in Salmonella serotypes
Isolates were deemed susceptible if no growth was observed on the antibiotic plate, resistant if there was confluent growth on the antibiotic plate and intermediate if growth was detectable but visibly less than on the control plate (no antibiotic added to the agar).
SSRL routinely uses two breakpoints of 0.125 and 0.5 mg/L for ciprofloxacin susceptibility testing due to the possible clinical significance of this important antimicrobial.
Susceptibility testing by Etest
Ciprofloxacin Etest strips (AB Biodisk, Solna, Sweden) were purchased from Biostat, Stockport, UK (product code 51000868) and stored at -20 C. Colonies taken from a fresh overnight CLED plate were resuspended in 3 mL of sterile 0.85% saline to a turbidity of 0.
Results
From a total of 2919 isolates of Salmonella received by SSRL in 1993, 40 (1.37%) were resistant to nalidixic acid (Table 1) .
Results from Etest MIC experiments demonstrated resistance to low-level ciprofloxacin (0.125 mg/L) in 33 (82.5%) of these isolates with two isolates of S. Hadar having MICs of 1.5 and 3 mg/L.
In 1998, the number of nalidixic acid-resistant isolates had risen to 186 (8.8%) from a total of 2109. The MIC of ciprofloxacin was measured by Etest and 173 (93%) were found to have reduced susceptibility. Two of the 173 isolates, both isolates of S. Typhimurium DT104, had high-level resistance with MICs of 0.5 mg/L (Table 1) .
Of the 1254 isolates received in 2003, 267 (21.3%) were nalidixic acid-resistant, 260 (97.4%) of which had reduced susceptibility to ciprofloxacin. Only four isolates of Salmonella were found to have MICs >0.5 mg/L in 2003: S. San-diego, 0.75 mg/L; S. Virchow and S. Haifa both 1 mg/L; S. Typhimurium DT RDNC, 12 mg/L ( Table 1 ). The distribution of the MICs of ciprofloxacin for nalidixic acid-resistant Salmonella isolates received by the SSRL in 1993, 1998 and 2003 is summarized in Figure 1 .
Overall, 11 (2.2%) isolates were resistant to ciprofloxacin at ‡0.5 mg/L and 433 (87.8%) had reduced susceptibility at 0.125 mg/L.
Of the 21 different serotypes identified, S. Enteritidis, S. Hadar, S. Typhimurium and S. Virchow were the four main contributors to the levels of nalidixic acid resistance seen in the 493 isolates investigated. S. Enteritidis was the most common, accounting for 72% of all isolates, followed by S. Hadar, S. Typhimurium and S. Virchow, which accounted for 8.9, 8.3 and 5.7% of the total, respectively. Levels of resistance to ciprofloxacin were also very high among these serotypes with 100% of S. Hadar, 95.5% of S. Enteritidis, 92.8% of S. Virchow and 82.9% of S. Typhimurium all resistant at ‡0.125 mg/L.
S. Enteritidis showed the greatest increase in resistance to nalidixic acid of any individual serotype over the 3 years studied. This was almost entirely due to S. Enteritidis phage type (PT) 1. In 1993, SSRL received 59 isolates of S. Enteritidis PT1 none of which were resistant to nalidixic acid. By 2003, 145 (72.9%) from a total of 199 were resistant at ‡40 mg/L. (Table 3 ). Crossresistance to ciprofloxacin at 0.125 mg/L mirrored this trend. In 1998, 74 (39.8%) of the 186 isolates studied were isolates of S. Enteritidis PT1, 70 (94.6%) of which were resistant to lowlevel ciprofloxacin. In 2003, 145 (54.3%) of 267 isolates were S. Enteritidis PT1, 140 (96.6%) being cross-resistant to ciprofloxacin at 0.125 mg/L. Over 50% of the S. Enteritidis PT1 isolates received by SSRL in 1998 were isolated from patients with a history of foreign travel (as indicated by epidemiological information submitted with the isolate), however, this had decreased in 2003 to 30%. This apparent decrease may be misleading in that (12.4) epidemiological information is rarely complete at the time of submission of the isolate to SSRL and therefore the number of patients with a history of foreign travel may be higher than it first appears. S. Enteritidis PT3 also showed a marked increase in nalidixic acid resistance. In 2003, SSRL received a total of 12 isolates, 11 of which were resistant to both nalidixic acid and ciprofloxacin at ‡0.125 mg/L (Table 4) . S. Enteritidis PT4 isolates decreased from 1385 in 1993 to 178 in 2003. However, nalidixic acid resistance rose from 1.5% of all S. Enteritidis PT4 isolates received by the SSRL to 12.4% in the same period. In 1993, 19 (90.5%) from a total of 21 nalidixic acidresistant S. Enteritidis PT4 were resistant at 0.125 mg/L concentrations of ciprofloxacin. In 2003, 100% of nalidixic acid-resistant S. Enteritidis PT4 had cross-resistance to low-level ciprofloxacin.
Discussion
The current NCCLS breakpoint for resistance to ciprofloxacin is ‡4 mg/L. However, due to the increasing number of treatment failures, it is becoming evident that this breakpoint may be concealing the true prevalence of resistance to ciprofloxacin. It has been suggested that the breakpoint should be lowered to 0.125 mg/L, as this would allow the detection of reduced susceptibility before high-level resistance becomes a problem. 18, 19 In this study, we showed that, of 40 isolates of nalidixic acid-resistant Salmonella from human sources received by the SSRL in 1993, 82.5% were cross-resistant to ciprofloxacin at 0.125 mg/L. By 2003, >97% of 267 isolates were resistant to both nalidixic acid and 0.125 mg/L ciprofloxacin.
In 1993, 47.5% of the isolates found to have reduced susceptibility to ciprofloxacin were S. Enteritidis PT4, which until recently was the most commonly isolated phage type from human Salmonella infections in Scotland. By 2003, this had decreased to only 8.8%. However, low-level ciprofloxacin resistance in S. Enteritidis PT1 had increased from zero in 1993 to 52% in 2003, mirroring the increased incidence of this phage type. This may be a result of expansion of a single nalidixic acid-resistant clone of S. Enteritidis PT1, as analysis of these isolates with PFGE all generate identical profiles (A. Murray and D. J. Brown, unpublished data). However, the increasing occurrence of quinolone resistance in S. Enteritidis isolates belonging to several different phage types indicates that the overall increase in quinolone resistance in this serotype is not due to the clonal expansion of a single resistant strain (Table 4) .
In 1993, SSRL received a single isolate of PT3, fully susceptible to both nalidixic acid and ciprofloxacin. However, in 2003, 11 from a total of 12 PT3 isolates were resistant to both nalidixic acid and 0.125 mg/L ciprofloxacin, of which 36% were isolated from people returning from foreign travel. Greater than 50% of 74 S. Enteritidis PT1 isolates were of foreign origin in 1998. This decreased to 30% of 145 S. Enteritidis PT1 isolates in 2003. Nevertheless, resistance to ciprofloxacin is increasingly being seen in isolates of foreign origin. Scientists in Finland have found that among foreign Salmonella isolates from travellers returning from Southeast Asia, ciprofloxacin resistance increased from 3.9 to 23%. 20 A study in Denmark also found that quinolone resistance in isolates from patients with a known history of foreign travel was 8.9% compared with 2.4% of domestically acquired infections. 14 No isolates of PT1 or PT4 had high-level resistance to ciprofloxacin. This appears to be true for most of the isolates investigated, since only 11 (2.2%) had MICs of ‡0.5 mg/L. Of six isolates of Salmonella found to have MICs >0.5 mg/L, two were isolated in 1993 and four were isolated in 2003. Resistance to nalidixic acid (a first-generation quinolone) in isolates of Salmonella is regarded as an indicator of decreased susceptibility to ciprofloxacin 21, 22 and is therefore often used as a screening tool. Recent reports have shown that high-level ciprofloxacin resistance is often a result of the sequential acquisition of mutations in a number of genes, namely gyrA, parC and parE 23 and less frequently in gyrB.
24
In order to avoid this sequence of events, it has been proposed that when administering quinolones for treatment of Salmonella infections, dosing strategies be based on a concentration that has been named the 'mutant prevention concentration' (MPC) and not on the MIC, which can allow the selection of antibiotic-resistant mutants. The MPC is defined as 'no colony recovery when 25 A recent study has proposed MPC values of ciprofloxacin for strains of S. Enteritidis and S. Typhimurium. 26 The occurrence of high-level fluoroquinolone resistance (ciprofloxacin ‡4 mg/L) in non-typhoidal Salmonella isolates remains rare worldwide but there have been increasing numbers of reports in recent years. 6, [27] [28] [29] Although relatively few isolates have tested resistant to high concentrations of ciprofloxacin in Scotland, we think there can be no doubt that the trend towards high-level resistance experienced in other countries will occur here too. The results of this study suggest it is imperative that surveillance of Salmonella isolates be continued at the breakpoint level of 0.125 mg/L, and we would suggest that the NCCLS reconsiders the recommended resistance breakpoint of 4 mg/L. We would also recommend that any resistance detected at or above the 0.125 mg/L breakpoint be confirmed by the MIC method. This is of particular importance when dealing with cases of typhoid fever or extra-intestinal sources.
